These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1358 related articles for article (PubMed ID: 10597619)

  • 1. Precision of estimates of an ADI (or TDI or PTWI).
    Speijers GJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of excursions above the ADI: duration in relation to pivotal studies.
    Walker R
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S114-8. PubMed ID: 10597624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Background to the ADI/TDI/PTWI.
    Herrman JL; Younes M
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
    Hasegawa R; Koizumi M; Hirose A
    Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of the risk of exceeding the acceptable or tolerable daily intake.
    Renwick AG; Walker R
    Regul Toxicol Pharmacol; 1993 Dec; 18(3):463-80. PubMed ID: 8128007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report of workshop on the significance of excursions of intake above the ADI.
    Larsen JC; Richold M
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S2-12. PubMed ID: 10597607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and severity in relation to magnitude of intake above the ADI or TDI: use of critical effect data.
    Renwick AG
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S79-86. PubMed ID: 10597618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of intake above the ADI/TDI in relation to toxicodynamics and toxicokinetics.
    Renwick AG
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S69-78. PubMed ID: 10597617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of excursions above the ADI. Case study: monosodium glutamate.
    Walker R
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S119-21. PubMed ID: 10597625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of excursions of intake above the acceptable daily intake: effect of time and dose in developmental toxicology.
    Sullivan FM
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S94-8. PubMed ID: 10597620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pesticide residue analysis and its relationship to hazard characterisation (ADI/ARfD) and intake estimations (NEDI/NESTI).
    Renwick AG
    Pest Manag Sci; 2002 Oct; 58(10):1073-82. PubMed ID: 12400449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excursions of intake above ADI: case study on cadmium.
    Nordberg G
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S57-62. PubMed ID: 10597615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical risk assessment and uncertainty associated with extrapolation across exposure duration.
    Pohl HR; Chou CH; Ruiz P; Holler JS
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):18-23. PubMed ID: 19944126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procedures for calculating benchmark doses for health risk assessment.
    Gaylor D; Ryan L; Krewski D; Zhu Y
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of an additional safety or uncertainty factor for nature of toxicity in the estimation of acceptable daily intake and tolerable daily intake values.
    Renwick AG
    Regul Toxicol Pharmacol; 1995 Dec; 22(3):250-61. PubMed ID: 8837849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine, and Denatonium Benzoate.
    Cosmetic Ingredient Review Expert Panel
    Int J Toxicol; 2008; 27 Suppl 1():1-43. PubMed ID: 18569160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism, variability and risk assessment.
    Dorne JL
    Toxicology; 2010 Feb; 268(3):156-64. PubMed ID: 19932147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intake of chemicals related to age in long-term toxicity studies--considerations for risk assessment.
    Luijckx NB; Rao GN; McConnell EE; Würtzen G; Kroes R
    Regul Toxicol Pharmacol; 1994 Aug; 20(1 Pt 1):96-104. PubMed ID: 7838994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.